Instrument Inactif

Autres langues CEL-SCI Corporation NYSE

Actions

US1508375086

Recherche biotechnologique et médicale

Autres langues

15/09	CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
17/08	CEL-SCI Reports Fiscal Third Quarter 2026 Results
14/08	Cel-Sci: Fiscal Q3 Earnings Snapshot
14/08	CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
04/08	CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
04/08	CEL-SCI Corporation Publishes Study Supporting Multikine Biomarker Strategy And Reports Survival Benefit In Oral Cancer
31/07	Certain Common Stock of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026.
31/07	Certain Warrants of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026.
31/07	Certain Stock Options of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026.
30/07	CEL-SCI Corporation Announces Oncology Journal Accepts for Publication New Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
30/07	Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
13/07	CEL-SCI Corporation Launches FDA Registration-Enabling Phase 3 Confirmatory Study of Multikine for Newly Diagnosed Head and Neck Cancer
13/07	CEL-SCI to Launch Confirmatory Study of Multikine
13/07	CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
24/06	CEL SCI : and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.-Saudi Cooperation in Cancer Care
24/06	CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
24/06	Cel-Sci Corporation and Saudi Amarox Sign Agreement for Multikine Commercialization in Saudi Arabia
16/06	CEL-SCI Closes $2.5 Million Stock Offering
16/06	CEL-SCI Announces Closing of Offering
16/06	CEL-SCI Corporation and Amarox Enter Distribution and Commercialization Agreement for Multikine in Saudi Arabia
16/06	CEL-SCI Corporation Advances Multikine Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study
16/06	CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
15/06	CEL-SCI Corporation Announces Pricing of Offering
12/06	CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
18/05	Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing